A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Q4 2024 Earnings Call Transcript March 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into ...

Reports Q4 revenue $$26.55M, consensus $6.48M.Cash and Investments: As of December 31 , Lexicon (LXRX) had $238M in cash and short-term ...

The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...

Neither of the selective SGLT2 inhibitors have yet been shown to reduce MI and stroke events. Sotagliflozin, however, inhibits SGLT2 as well as gastrointestinal SGLT1; the latter effect, the study ...

As per their name, entry/attachment inhibitors work by blocking the virus's ability to attach to or enter healthy host cells. They do so by binding to different receptors on the surface of the host ...

Unlike other SGLT2 inhibitors, it uniquely blocks both SGLT1 and SGLT2, offering distinct cardiovascular benefits. Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients ...